Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index; 5 of the 13 sources its claims cite were checked for support.
Abstract
A library of drugs that are in clinical trials or use was screened for inhibitors of hypoxia-inducible factor 1 (HIF-1). Twenty drugs inhibited HIF-1-dependent gene transcription by >88% at a concentration of 0.4 microM. Eleven of these drugs were cardiac glycosides, including digoxin, ouabain, and proscillaridin A, which inhibited HIF-1alpha protein synthesis and expression of HIF-1 target genes in cancer cells. Digoxin administration increased latency and decreased growth of tumor xenografts, whereas treatment of established tumors resulted in growth arrest within one week. Enforced expression of HIF-1alpha by transfection was not inhibited by digoxin, and xenografts derived from these cells were resistant to the anti-tumor effects of digoxin, demonstrating that HIF-1 is a critical target of digoxin for cancer therapy.
Overview
CoChat Summary
TL;DR
A screen of 3,120 clinically used or trial drugs identified cardiac glycosides, including digoxin, as potent inhibitors of HIF-1α protein synthesis. Digoxin blocked HIF-1 target gene expression and inhibited tumor xenograft growth, with resistance in cells expressing HIF-1α from a transfected vector lacking HIF-1α mRNA untranslated regions.
Key findings
- In a Hep3B-c1 reporter screen, 336 of 3,120 drugs reduced hypoxia-induced firefly/Renilla luciferase activity by ≥50% at 10 µM; after re-screening, the top 20 drugs caused ≥88% inhibition at 0.4 µM, and 11 of these 20 were cardiac glycosides, including digoxin, ouabain, and proscillaridin A.
- Cardiac glycosides inhibited hypoxia-induced HIF-1α and HIF-2α protein expression at concentrations ≥50 nM and decreased mRNA levels of HIF-1 target genes HK1, HK2, and GLUT1 at 1% O2, without inhibiting HIF-1α mRNA.
- Digoxin inhibited HIF-1α protein synthesis independently of the PHD-VHL-proteasome pathway, mTOR/RPS6, Na+/K+ ATPase α1, and topoisomerases; pulse-labeling showed digoxin reduced de novo HIF-1α synthesis by 73% while overall protein synthesis was inhibited by only 19%.
- In SCID mouse xenografts, daily i.p. digoxin at 0.5 or 2 mg/kg inhibited P493-Myc tumor growth dose-dependently; 2 mg/kg inhibited PC3 tumor growth, and delayed treatment of established tumors (mean volume 100 mm3) caused growth arrest within 7 days. PC3-CA5 xenografts expressing constitutively active HIF-1α were resistant to digoxin’s anti-tumor effect.
Methods
- Cell-based screen using Hep3B-c1 cells stably transfected with an HRE-driven firefly luciferase reporter and a constitutive Renilla luciferase reporter; the Hopkins Drug Library of 3,120 FDA-approved or phase II drugs was screened at 10 µM, then re-screened at 2 µM and 0.4 µM.
- Mechanistic assays included immunoblotting for HIF-1α/HIF-2α, quantitative real-time RT-PCR for HIF-1 target mRNAs, [35S]methionine/cysteine pulse-labeling with HIF-1α immunoprecipitation, shRNA knockdown of Na+/K+ ATPase α1 and topoisomerases, flow cytometry, and annexin V staining.
- In vivo studies used SCID mice bearing P493-Myc, PC3-EV, or PC3-CA5 xenografts; digoxin was administered by daily intraperitoneal injection, with tumor volume, body weight, tumor HIF-1α protein, and HIF-1 target gene mRNAs assessed.
Limitations
- The paper states that digoxin has both HIF-1α-dependent and HIF-1α-independent effects on cell growth, based on PC3-CA5 cells growing similarly to vehicle-treated PC3-EV cells.
- Evident from the text: the mechanistic and in vivo work relies on specific cell lines and SCID mouse xenograft models, with no human clinical outcomes reported.
- The provided text is truncated before the end of the Discussion, so any additional limitations stated there are not available.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
5 Valid · 0 Not valid · 4 Not checked · 18 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HIF-1 also controls the expression of genes involved in tumor cell immor- talization, stem cell maintenance/de-differentiation, genetic in- stability, autocrine growth, invasion/metastasis, and treatment failure (6, 7).”
What the sources say
- Not checked — no full text of the sourcecites [6] matched to “Evaluation of HIF-1 inhibitors as anticancer agents” (2007) source
- Partly supportedcites [7] matched to “The role of hypoxia-inducible factors in tumorigenesis” (2008) sourceExperimental — accuracy not yet measured
The Figure 3 caption (Angiogenesis section; page not provided) says HIF-regulated genes contribute to proliferation, invasion, and metastasis, and the Differentiation discussion links HIF signaling to an undifferentiated state. But the review does not establish that HIF-1 controls genes for every listed outcome: it attributes direct Oct4 regulation to HIF-2, does not substantiate immortalization or genetic instability, and describes HIF-1’s effects on radiotherapy response as mixed rather than simply causing treatment failure. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Digitoxin inhibited the development of skin pap- illomas in mice treated with dimethylbenzanthracene and tetra- decanoylphorbol ester (34).”
What the sources say
- Supportedcites [34] matched to “Anti-tumor Promoting Activities of Natural Products. II. Inhibitory Effects of Digitoxin on Two-Stage Carcinogenesis of Mouse Skin Tumors and Mouse Pulmonary Tumors.” (1993) source
The Results and Discussion (p. 1) report that digitoxin delayed skin papilloma formation and reduced both the proportion of mice bearing papillomas and the average number per mouse. The figure caption on the same page identifies DMBA as the initiator and TPA as the promoter. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The growth of digoxin-treated PC3-CA5 cells was similar to that of vehicle-treated PC3-EV cells.”
§ 4 h pretreatment > 1.00 0.31 0.270.12
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“When Hep3B-c1 cells were cultured under hypoxic conditions (1% O2), the ratio of firefly/Renilla luciferase activity was ten-fold higher than when the cells were cultured under nonhy- poxic conditions (20% O2) for 24 h (Fig. 1B).”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Similar results were obtained in Hep3B cells treated with 100 nM digoxin (Fig. 1G).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
10 more claims
Create a free account to see all 27 claims and every source verdict.
- Probably not a substantial claim. 5
- It may state two separate claims as one. 7
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Likewise, pharmacologic depletion of HIF1α by small molecules PX478 and Digoxin41,42 also produced similar results in T and NK cells (Fig. 4g, h and Fig. S5f, g, h).”
From Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy (2022) · cites this paper as [41]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Digoxin, which is currently passing phase I clinical trials, was reported to inhibit established tumor xenografts with no effect on the growth of constitutively expressing HIF-1 xenografts.”
From HIF-1α pathway: role, regulation and intervention for cancer therapy (2015) · cites this paper as [60]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In vivo, digoxin inhibits tumor growth and suppresses lung metastasis in orthotopic breast cancer models [295,297].”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [295]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In HepB cells, these agents reduced both HIF-1α and HIF-2α protein levels without altering HIF1A mRNA, indicating post-transcriptional regulation [295].”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [295]
Experimental — accuracy not yet measuredIn the citing paper
“One significant hurdle for the use of these compounds, however, is the lack of specificity of these compounds for specific blockade of HIF (such as digoxin, acriflavine, and 17-AAG) identified to date [124–126].”
From Hypoxia and hypoxia-inducible factors as regulators of T cell development, differentiation, and function (2013) · cites this paper as [125]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212 · cited 1×
“HIF-1 is a heterodimeric protein that is composed of O2regulated HIF-1 and constitutively expressed HIF-1 subunits (8, 9).”
Self-citationThe tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180 · cited 1×
“VHL loss-of-function results in constitutive expression of HIF-1 in the majority of clear cell renal carcinomas (11).”
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
Kaelin, W. G., & Ratcliffe, P. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.009 · Cited by 3,251 · cited 1×
“Under normoxic conditions, HIF-1 is hydroxylated on proline residue 564 and/or 402 by proline hydroxylase domain protein 2 (PHD2), which is required for the binding of the von Hippel-Lindau protein (VHL), the recognition subunit of an E3 ubiquitin-protein ligase that targets HIF-1 for proteasomal degradation (10).”
Hypoxia in cancer: significance and impact on clinical outcome
Vaupel, P., & Mayer, A. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9055-1 · Cited by 2,240
(1999) · PubMed · Cited by 2,204
Self-citationPurification and Characterization of Hypoxia-inducible Factor 1
Wang, G. L., & Semenza, G. L. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.3.1230 · Cited by 2,073
Self-citationRas, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019 · cited 1×
“Whereas VHL loss-of-function leading to dysregulated HIF-1 expression is restricted to renal cell carcinoma and cerebellar hemangioblastoma, many common human cancers have mutations in phosphatidylinositol 3-kinase or upstream signaling pathways (13).”
Semenza, G. L., Jiang, B.-H., Leung, S. W., Passantino, R., Concordet, J.-P., Maire, P., & Giallongo, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.51.32529 · Cited by 1,752
Self-citationTalks, K. L., Turley, H., Gatter, K. C., Maxwell, P. H., Pugh, C. W., Ratcliffe, P. J., & Harris, A. L. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64554-3 · Cited by 1,312
Cited by
Items 301–400 of 620
Sensing the oxygen and temperature in the adipose tissues – who’s sensing what?
Kang, G.-S., Jo, H.-J., Lee, Y.-R., Oh, T., Park, H.-J., & Ahn, G. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01113-x · Cited by 37
“…inhibiting the activity of the sodium-potassium ATPase pump, also identi fi ed through compound library screening as a small molecule HIF-1 inhibitor 60 , has been reported to prevent diet-induced obesity in mice, although the suggested mechanism is through inhibition of the IL-17A phosphorylation…”
BackgroundKnowles, H. J. (2020) · Scientific Reports · doi:10.1038/s41598-020-78003-z · Cited by 37
Barh, D., Aljabali, A. A. A., Tambuwala, M. M., Tiwari, S., Serrano‐Aroca, Á., Alzahrani, K. J., Andrade, B. S., Azevedo, V., Ganguly, N. K., & Lundstrom, K. H. (2021) · Biomedicines · doi:10.3390/biomedicines9050556 · Cited by 36
“Digoxin blocked the transcription factor hypoxia-inducible factor 1 (HIF-1) to inhibit tumor growth [92].”
BackgroundCardiac Glycoside Ouabain Exerts Anticancer Activity via Downregulation of STAT3
Du, J., Jiang, L., Chen, F., Hu, H., & Zhou, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.684316 · Cited by 43
“The mechanisms of these anticancer effects may include induction of cell cycle arrest (24); inhibition of IL-8 production and of the NF-kB pathway (25); activation of the AMPK-Src signaling pathway (26) and suppression of HIF-1a protein synthesis (27).”
BackgroundZhang, J., Sharma, D., Dinabandhu, A., Sanchez, J. C., Applewhite, B. P., Jee, K. J., Deshpande, M. M., Flores‐Bellver, M., Hu, M.-W., Guo, C., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci163290 · Cited by 37
“Treatment of mice with the pharmacologic HIF inhibitor digoxin (36) prevented retinal NV in the OIR model (Figure 2A) by inhibiting the sequential accumulation of HIF-1 α or HIF-2 α (14).”
Self-citationDeletion of Phd2 in Myeloid Lineage Attenuates Hypertensive Cardiovascular Remodeling
Ikeda, J., Ichiki, T., Matsuura, H., Inoue, E., Kishimoto, J., Watanabe, A., Sankoda, C., Kitamoto, S., Tokunou, T., Takeda, K., et al. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000178 · Cited by 39
Pirkmajer, S., Bezjak, K., Matkovič, U., Dolinar, K., Jiang, L. Q., Miš, K., Gros, K., Милованова, К. Г., Pirkmajer, K. P., Marš, T., et al. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.566584 · Cited by 35
“…subunit of the heterodimeric transcription factor HIF-1 (HIF-1α/HIF-1β) (Samanta and Semenza, 2017), suppresses the phosphorylation of STAT3 in fibroblasts (Gao et al., 2015), while ouabain reduces HIF-1α levels in cancer and smooth muscle cells (Zhang et al., 2008; Koltsova et al., 2014).”
BackgroundFunctional regulation of hypoxia inducible factor-1α by SET9 lysine methyltransferase
Liu, Q., Geng, H., Xue, C., Beer, T. M., & Qian, D. Z. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.01.011 · Cited by 35
Self-citationDifferential response to exercise in claudin-low breast cancer
Glass, O. K., Bowie, M., Fuller, J., Darr, D., Usary, J., Boss, K., Choudhury, K. R., Liu, X., Zhang, Z., Locasale, J. W., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21054 · Cited by 32
“To investigate the importance of Hif1-α in exerciseinduced growth acceleration of C3(1)SV40Tag-p16-luc tumors, we used the cardiac glycoside, digoxin, to inhibit synthesis of Hif1-α protein [16, 17].”
MethodTargeting hypoxia in the treatment of small cell lung cancer
Bryant, J., Meredith, S. L., Williams, K. J., & White, A. E. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.08.003 · Cited by 38
Cardiac glycosides block cancer growth through HIF-1α- and NF-κB-mediated Plk1
Xie, C., Liu, X., Yu, S. S. B., & Cheng, C. H. K. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt136 · Cited by 33
Xu, R., Han, M., Xu, Y., Zhang, X., Zhang, C., Zhang, D., Ji, J., Wei, Y., Wang, S., Huang, B., et al. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1266-9 · Cited by 44
WWOX controls hepatic HIF1α to suppress hepatocyte proliferation and neoplasia
Abu‐Remaileh, M., Khalaileh, A., Pikarsky, E., & Aqeilan, R. I. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0510-4 · Cited by 37
HIF-Dependent Mechanisms of Relationship between Hypoxia Tolerance and Tumor Development
Dzhalilova, D. S., & Makarova, O. V. (2021) · Biochemistry (Moscow) · doi:10.1134/s0006297921100011 · Cited by 39
Hussain, K., Liu, R., Smith, R. C. G., Müller, K. T. J., Ghorbani, M., Macari, S. A., Cleary, K. L. S., Oldham, R. J., Foxall, R. B., James, S., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02294-5 · Cited by 36
“Digoxin has been reported to inhibit HIF-1α translation [86, 87] and we observed significant inhibition of FcγRIIb upregulation (p < 0.”
BackgroundBohonowych, J. E., Peng, S., Gopal, U., Hance, M. W., Wing, S. B., Argraves, K. M., Lundgren, K., & Isaacs, J. S. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-520 · Cited by 32
“A number of generalized HIF targeted approaches have been employed, including modulation of HIF expression, transcription, translation, dimerization, transactivation, and stability [17-23].”
BackgroundCombined treatment targeting HIF‐1α and Stat3 is a potent strategy for prostate cancer therapy
Reddy, K. R., Guan, Y., Qin, G., Zhou, Z., & Jing, N. (2011) · The Prostate · doi:10.1002/pros.21397 · Cited by 34
“Semenza group indentified several drugs that inhibit HIF-1, such as digoxin that inhibits HIFa protein synthesis [31] and acriflavine (ACF) that inhibits dimerization of HIF protein [32].”
BackgroundLopez-Lazaro, M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813047106 · Cited by 32
Bousquet, M. S., Ma, J., Ratnayake, R., Havre, P. A., Yao, J. G., Dang, N. H., Paul, V. J., Carney, T. J., Dang, L. H., & Luesch, H. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b00860 · Cited by 34
Targeting UHRF1-dependent DNA repair selectively sensitizes KRAS mutant lung cancer to chemotherapy
Tian, D., Tang, J., Geng, X., Li, Q., Wang, F., Zhao, H., Narla, G., Yao, X., & Zhang, Y. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.08.008 · Cited by 35
Nacev, B. A., & Liu, J. O. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024793 · Cited by 33
Self-citationPersonalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice
Kamiyama, H., Rauenzahn, S. L., Shim, J. S., Karikari, C. A., Feldmann, G., Hua, L., Kamiyama, M., Schuler, F. W., Lin, M., Beaty, R. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2127 · Cited by 33
Self-citationCucurbitacin B inhibits the translational expression of hypoxia-inducible factor-1α
Ma, J., Jiang, Y. Z., Shi, H. R., Mi, C., Li, J., Nan, J., Wu, X. Z., Lee, J. J., & Jin, X. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.12.005 · Cited by 36
Cheng, C.-F., Lu, I.-H., Tseng, H., Sun, C.-Y., Lin, L.-T., Kuo, Z., Pan, I.-H., & Ko, C.-H. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/958025 · Cited by 32
Identification of Cardiac Glycoside Molecules as Inhibitors of c-Myc IRES-Mediated Translation
Didiot, M.-C., Hewett, J. W., Varin, T. V., Freuler, F., Selinger, D. W., Nick, H., Reinhardt, J., Buckler, A., Myer, V. E., Schuffenhauer, A., et al. (2012) · SLAS DISCOVERY · doi:10.1177/1087057112466698 · Cited by 33
“Cardiac glycosides have been shown previously to be potent inhibitors, at the level of translation, of the expression of the tumor suppressor p53 as well as the hypoxiainducible transcription factor 1 (HIF-1) in hypoxic tumor cells.(25,26) It was shown that digoxin very potently inhibits M SO m po un d 4”
BackgroundJiang, W., Li, G., Li, W., Wang, P., Xiu, P., Jiang, X. L., Liu, B., Sun, X., & Jiang, H. (2018) · Scientific Reports · doi:10.1038/s41598-018-28010-y · Cited by 33
Fakhri, S., Moradi, S. Z., Faraji, F., Kooshki, L., Webber, K. J., & Bishayee, A. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10136-9 · Cited by 34
Pirkmajer, S., Filipović, D., Marš, T., Miš, K., & Grubič, Z. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00133.2010 · Cited by 32
Кольцова, С. В., Shilov, B. V., Birulina, J. G., Akimova, O. A., Haloui, M., Капилевич, Л. В., Gusakova, S. V., Tremblay, J., Hamet, P., & Orlov, S. N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110597 · Cited by 36
“demonstrated in other cell types studied so far [22;41], hypoxia slightly augmented Hif-1a mRNA (Table 4) and increased immunoreactive HIF-1a protein content by ,5-fold (Fig.”
BackgroundFu, Y.-C., & Xin, Z. (2018) · Bioscience Reports · doi:10.1042/bsr20180552 · Cited by 30
RetractedLi, Y., & Li, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.629614 · Cited by 33
Ren, Y., Wu, S., Burdette, J. E., Cheng, X., & Kinghorn, A. D. (2021) · Molecules · doi:10.3390/molecules26123672 · Cited by 32
“Digoxin was found to inhibit HIF-1α effectively to suppress tumor growth [36], and it also prohibited HIF-1α synthesis, vascular endothelial growth factor (VEGF), and N-Myc downregulated gene 1 (NDRG1) in A549 human lung cancer cells to show its cytotoxicity [37]; it suppressed HIF-1α and blood vessel formation in C4-…”
BackgroundSelf-citationOxygen tension level and human viral infections
Morinet, F., Casetti, L., François, J.-H., Capron, C., & Pillet, S. (2013) · Virology · doi:10.1016/j.virol.2013.06.018 · Cited by 32
Jalouli, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041752 · Cited by 34
Cardiac Glycosides: From Natural Defense Molecules to Emerging Therapeutic Agents
Ponce, A., Flores-Maldonado, C., & Contreras, R. G. (2025) · Biomolecules · doi:10.3390/biom15060885 · Cited by 42
“The anti-tumor effects of digoxin were reversed in cells overexpressing HIF-1 α , confirming functional relevance [108].”
Liu, T., Zhao, L., Hou, H., Ding, L., Chen, W., & Li, X. (2017) · Tumor Biology · doi:10.1177/1010428317692225 · Cited by 31
Revisiting the role of hypoxia-inducible factors in pulmonary hypertension
Shimoda, L. A., Yun, X., & Sikka, G. (2019) · Current Opinion in Physiology · doi:10.1016/j.cophys.2018.12.003 · Cited by 31
“For example, digoxin, which inhibits HIF-1 transcriptional activity by preventing HIF-1a protein accumulation [82], attenuated hypoxic induction of HIF-1 target genes in lungs from chronically hypoxic animals and in PASMCs exposed to hypoxia ex vivo and prevented PH in mice exposed to CH [83].”
Terraneo, L., Virgili, E., Caretti, A., Bianciardi, P., & Samaja, M. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.03.019 · Cited by 34
“Whereas a HIF-1 inhibitor, digoxin, has been used or decades in the treatment of prostate cancer (Zhang et al., 2008), nother inhibitor, topotecan, failed to show significant anticancer ffects in clinical trials, despite the drug hits its target (Kummar t al., 2011).”
BackgroundKasper, A. C., Moon, E. J., Hu, X., Park, Y., Wooten, C. M., Kim, H., Yang, W., Dewhirst, M. W., & Hong, J. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.04.071 · Cited by 32
Chansu inhibits the expression of cortactin in colon cancer cell lines in vitro and in vivo
Li, C., Hashimi, S. M., Cao, S., Qi, J., Good, D. M., Duan, W., & Wei, M. Q. (2015) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-015-0723-3 · Cited by 30
“Moreover, we established the effects of CBF treatment under both hypoxic and normoxic conditions, as several of these ion pump inhibitors, including digoxin and ouabain, have been shown to play an anti-cancer role by diminishing hypoxia-inducible factor 1 alpha (HIF-1α) expression [16, 17].”
BackgroundWissing, M. D., Dadon, T., KIM, E., PIONTEK, K. B., Shim, J. S., Kaelber, N. S., Liu, J. O., Kachhap, S. K., & Nelkin, B. D. (2014) · Oncology Reports · doi:10.3892/or.2014.3174 · Cited by 30
“Several compounds from the JHDL have been advanced to clinical trials for cancer and other therapeutic applications (13,14,16,17,30-32).”
BackgroundMethodSelf-citationRasheduzzaman, M., Yin, H., & Park, S. (2019) · Molecular Carcinogenesis · doi:10.1002/mc.23096 · Cited by 29
Cardiac glycosides with target at direct and indirect interactions with nuclear receptors
Karaś, K., Sałkowska, A., Dastych, J., Bachorz, R. A., & Ratajewski, M. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110106 · Cited by 31
NARF is a hypoxia-induced coactivator for OCT4-mediated breast cancer stem cell specification
Yang, Y., Chen, C. O., Zuo, Q., Lu, H., Salman, S., Lyu, Y., Huang, T. Y.-T., Wicks, E. E., Jackson, W., Datan, E., et al. (2022) · Science Advances · doi:10.1126/sciadv.abo5000 · Cited by 30
Self-citationPsychotropic agent thioridazine elicits potent in vitro and in vivo anti-melanoma effects
Jiang, X., Chen, Z., Shen, G., Jiang, Y., Wu, L., Li, X., Wang, G., & Yin, T. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.11.012 · Cited by 28
Recent Advances in Drug Delivery System for Bioactive Glycosides from Traditional Chinese Medicine
Li, L., Feng, Y., Hong, Y., Lin, X., & Shen, L. (2018) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x18500908 · Cited by 26
Brownfoot, F., Tong, S., Hannan, N. J., Hastie, R. M., Cannon, P., Tuohey, L., & Kaitu’u‐Lino, T. J. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.06.033 · Cited by 33
Moinuddin, A., Poznanski, S. M., Portillo, A. L., Monteiro, J. K., & Ashkar, A. A. (2024) · Immunological Reviews · doi:10.1111/imr.13316 · Cited by 34
Interplay between receptor tyrosine kinases and hypoxia signaling in cancer
Glück, A. A., Aebersold, D. M., Zimmer, Y., & Medová, M. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.02.018 · Cited by 30
“Interestingly, xenografts derived from cells with HIF-1α enforced expression were resistant to the anti-tumor effect of digoxin, showing that HIF-1α is the critical target of digoxin for cancer therapy [172].”
Background55th Bowditch Lecture: Effects of chronic hypoxia on the pulmonary circulation: Role of HIF-1
Shimoda, L. A. (2012) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00843.2012 · Cited by 32
Repurposing Cardiac Glycosides: Drugs for Heart Failure Surmounting Viruses
Škubník, J., Bejček, J., Pavlíčková, V. S., & Rimpelová, S. (2021) · Molecules · doi:10.3390/molecules26185627 · Cited by 30
Hypoxia-inducible factor 1α regulates branching morphogenesis during kidney development
Tsuji, K., Kitamura, S., & Makino, H. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.03.111 · Cited by 27
“Because recent research has shown that digoxin inhibits HIF-1α-dependent gene transcription [18], we used digoxin as an HIF-1α inhibitor.”
MethodManresa, M. C., Tambuwala, M. M., Radhakrishnan, P., Harnoss, J. M., Brown, E., Cavadas, M. A. S., Keogh, C. E., Cheong, A., Barrett, K. E., Cummins, E. P., et al. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00229.2016 · Cited by 32
“As previously 461 demonstrated, digoxin and camptothecin reduced HIF-1α in DMOG treated 462 cells(8, 46, 76).”
BackgroundResultDigoxin and its Na+/K+-ATPase-targeted actions on cardiovascular diseases and cancer
Ren, Y., Anderson, A. T., Meyer, G., Lauber, K. M., Gallucci, J. C., & Kinghorn, A. D. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117939 · Cited by 33
Self-citationHIF Inhibition Therapy in Ocular Diseases
Lee, D., Miwa, Y., Kunimi, H., Ibuki, M., Shoda, C., Nakai, A., & Kurihara, T. (2021) · The Keio Journal of Medicine · doi:10.2302/kjm.2021-0004-ir · Cited by 30
Zheng, Q., Lu, W., Yan, H., Duan, X., Chen, Y., Zhang, C., Luo, X., Chen, J., Wang, C., Liu, S., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15696 · Cited by 27
“Pharmacological inhibition of HIF-1α by digoxin, which inhibits HIF-1α protein accumulation (Zhang et al., 2008), prevents mice from developing PH or reverses established PH in mice (Abud et al.”
BackgroundMi, C., Ma, J., Shi, H. R., Li, J., Wang, F., Lee, J. J., & Jin, X. (2014) · Journal of Pharmacological Sciences · doi:10.1254/jphs.13273fp · Cited by 27
Zheng, H., Yang, J., Hou, Y., Sun, B., ZHANG, Q., Mou, Y., WAND, L., & Wu, C. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2744 · Cited by 27
Lin, J., Zhan, T., Duffy, D., Hoffman-Censits, J. H., Kilpatrick, D. L., Trabulsi, E. J., Lallas, C. D., Chervoneva, I., Limentani, K., Kennedy, B., et al. (2014) · PubMed · Cited by 32
HIF inhibitors for ischemic retinopathies and cancers: options beyond anti-VEGF therapies
Subhani, S., Vavilala, D. T., & Mukherji, M. (2016) · Angiogenesis · doi:10.1007/s10456-016-9510-0 · Cited by 28
“This study has established that cardiac glycosides inhibit the HIF pathway by blocking the HIF-1a protein synthesis leading to retarded growth of prostate cancer cells in a tumor xenograft [128].”
BackgroundSánchez‐Sánchez, L., Hernández-Linares, M. G., Escobar, M. L., López‐Muñoz, H., Zenteno, E., Fernández‐Herrera, M. A., Guerrero‐Luna, G., Carrasco‐Carballo, A., & Sandoval-Ramı́rez, J. (2016) · Molecules · doi:10.3390/molecules21111533 · Cited by 27
Ma, L., Meng, Y., Tu, C., Cao, X., Wang, H., Li, Y., Man, S., Zhou, J., Li, M., Liu, Z., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.09.019 · Cited by 27
Hsu, C.-W., Huang, R., Khuc, T., Shou, D., Bullock, J., Grooby, S., Griffin, S., Zou, C., Little, A. S., Astley, H. M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6995 · Cited by 29
DIMAS, K. S., Papadopoulou, N., Baskakis, C., Prousis, K. C., Tsakos, M., Alkahtani, S. H., Honisch, S., Lang, F. J. W., Calogeropoulou, T., Alevizopoulos, K., et al. (2014) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/18715206113136660338 · Cited by 25
“Recent chemical screening and epidemiological data with digitalis compounds point to a strong anti-cancer potential of these inhibitors in various cancer indications such as breast, prostate cancer and leukemia/lymphoma [22-24, 39, 41, 42] Based on these results, Na/K ATPase inhibitors are emerging as promising new an…”
BackgroundA cohort study of digoxin exposure and mortality in men with prostate cancer
Flahavan, E. M., Sharp, L., Bennett, K., & Barron, T. I. (2013) · British Journal of Urology · doi:10.1111/bju.12287 · Cited by 26
Callus culture and in vitro biosynthesis of cardiac glycosides from Calotropis gigantea (L.) Ait
Tripathi, P. K., Awasthi, S., Kanojiya, S., Tripathi, V., & Mishra, D. K. (2012) · In Vitro Cellular & Developmental Biology - Plant · doi:10.1007/s11627-012-9481-9 · Cited by 25
“More recently, CGs have been reported to have anti-proliferative activity on tumor cell lines and are potential targets for cancer chemotherapy (Newman et al. 2008; Zhang et al. 2008; Hallbook et al. 2011).”
BackgroundMartin, A. R., Ronco, C., Demange, L., & Benhida, R. (2017) · MedChemComm · doi:10.1039/c6md00432f · Cited by 30
Elmacı, İ., Emekli‐Alturfan, E., Cengiz, S., Özpınar, A., & Altinoz, M. A. (2018) · International Journal of Neuroscience · doi:10.1080/00207454.2018.1435540 · Cited by 28
“with 11 of these being cardiac glycosides [38].”
BackgroundRahman, M. A., Jalouli, M., Bhajan, S. K., Al-Zharani, M. M., & Harrath, A. H. (2025) · Cells · doi:10.3390/cells14060437 · Cited by 33
Non-classical cardenolides from Calotropis gigantea exhibit anticancer effect as HIF-1 inhibitors
Zheng, Z., Zhou, Z., Zhang, Q., Zhou, X., Yang, J., Yang, M.-R., Zhu, G., Jiang, Z., Li, T., Lin, Q., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104740 · Cited by 25
Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing
Bahmad, H. F., Demus, T., Moubarak, M. M., Daher, D., Moreno, J. C. A., Polit, F., López, O., Merhe, A., Abou-Kheir, W. G., Nieder, A. M., et al. (2022) · Medical Sciences · doi:10.3390/medsci10010015 · Cited by 35
Vavilala, D. T., Ponnaluri, V. K. C., Kanjilal, D., & Mukherji, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113717 · Cited by 26
“rapamycin [45], digoxin [46], 2-methoxyestradiol [47], topotecan [48], NSC644221 [49], EZN-2968 [50], etc.”
Hurst, J. H. (2016) · Journal of Clinical Investigation · doi:10.1172/jci90055 · Cited by 32
Pollard, H., Yang, Q., Dalgard, C. L., Eidelman, O., Jozwik, C., Pollard, B., & Srivastava, M. (2013) · Journal of Carcinogenesis · doi:10.4103/1477-3163.112268 · Cited by 24
“of P493‐Myc and PC‐3 prostate tumor xenografts in SCID mice.[38] Finally, independently of the cardiac glycoside narrative, Walczak‐Drzeweicka et al.”
BackgroundGarcia, I. J. P., de Oliveira, G. C., Valadares, J. M. M., Banfi, F. F., Andrade, S. N., Freitas, T. R., Filho, E. D. S. M., Santos, H. D. L., Júnior, G. M. V., Chaves, M. H., et al. (2019) · Steroids · doi:10.1016/j.steroids.2019.108490 · Cited by 26
Molecular pathogenesis of bone metastases in breast cancer: Proven and emerging therapeutic targets
Rucci, N., Sanità, P., Monache, S. D., Alesse, E., & Angelucci, A. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i3.335 · Cited by 26
Antagonistic role of natural compounds in mTOR-mediated metabolic reprogramming
Cerella, C., Gaigneaux, A., Dicato, M. A., & Diederich, M. F. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.02.008 · Cited by 26
Kwon, D.-Y., Lee, H., Weitzel, D. H., Park, K., Lee, S. H., Lee, C.-T., Stephenson, T. N., Park, H., Fitzgerald, M. C., Chi, J., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01220 · Cited by 29
Wu, J., Zhang, Z., Zhang, L.-H., Jin, X., Ma, J., & Piao, H. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.12.060 · Cited by 23
Hypoxia-inducible factor-1α restricts the anabolic actions of parathyroid hormone
Frey, J. L., Stonko, D. P., Monier‐Faugere, M., & Riddle, R. C. (2014) · Bone Research · doi:10.1038/boneres.2014.5 · Cited by 26
Liu, B., Anderson, S. L., Qiu, J., & Rubin, B. Y. (2013) · FEBS Journal · doi:10.1111/febs.12355 · Cited by 23
Cytotoxic and HIF-1α Inhibitory Compounds from Crossosoma bigelovii
Klausmeyer, P., Zhou, Q., Scudiero, D. A., Uranchimeg, B., Melillo, G., Cardellina, J. H., Shoemaker, R. H., Chang, C., & McCloud, T. G. (2009) · Journal of Natural Products · doi:10.1021/np8006342 · Cited by 24
Einbond, L. S., Wu, H., Sandu, C., Ford, M., Mighty, J., Antonetti, V., Redenti, S., & Ma, H. (2015) · Fitoterapia · doi:10.1016/j.fitote.2015.12.005 · Cited by 26
Khodair, A. I., Attia, A. M. E., Gendy, E. A., Elshaier, Y. A. M. M., & El‐Magd, M. A. (2019) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.3527 · Cited by 24
Kim, H.-J., Cho, H., Ban, H. S., & Nakamura, H. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.01.031 · Cited by 25
Chen, C., Zhu, G., Wang, J., & Jiang, Z. (2016) · RSC Advances · doi:10.1039/c6ra16455b · Cited by 22
Specific inhibition of HIF activity: can peptides lead the way?
Mylonis, I., Chachami, G., & Simos, G. (2021) · Cancers · doi:10.3390/cancers13030410 · Cited by 21
“, digoxin) [91], topoisomerase inhibitors (e.”
Translational aspects in targeting the stromal tumour microenvironment: From bench to bedside
Bhome, R., AlSaihati, H., Goh, R. W., Bullock, M. D., Primrose, J. M., Thomas, G. J., Sayan, E., & Mirnezami, A. H. (2016) · European Journal of Molecular & Clinical Medicine · doi:10.1016/j.nhtm.2016.03.001 · Cited by 23
“Consequently, digoxin has been found to inhibit HIF-1α ([166]).”
BackgroundHonokiol inhibits pathological retinal neovascularization in oxygen-induced retinopathy mouse model
Vavilala, D. T., O’Bryhim, B. E., Ponnaluri, V. K. C., White, R. S., Radel, J. D., Symons, R. C. A., & Mukherji, M. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.07.118 · Cited by 20
Na+/H+Exchange and Hypoxic Pulmonary Hypertension
Huetsch, J., & Shimoda, L. A. (2015) · Pulmonary Circulation · doi:10.1086/680213 · Cited by 20
“Cardiac glycosides, including digoxin, have been found to decrease HIF-1α protein expression via inhibition of HIF-1α mRNA translation.(156) Acriflavine, which historically was used as a topical antiseptic, also inhibited HIF-1 function, though via a different mechanism: it inhibits dimerization of HIF-1α with HIF-1β,…”
BackgroundTh17/Treg immunoregulation and implications in treatment of sulfur mustard gas-induced lung diseases
Iman, M., Rezaei, R., Jamalkandi, S. A., Shariati, P., Kheradmand, F., & Salimian, J. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1389646 · Cited by 25
“Digoxin 1 HIF1α Reduce the expression of HIF-1 [155] YC-1 stimulator (sGC)2 Soluble guanylyl cycle Inhibition DNA-binding activity of HIF-1 [156] Vincristine Microtubules Disrupts the microtubular system [157] Acriflavine HIF-1alpha and HIF-2alpha Preventing HIF-1α/HIF-1β dimer formation [158] Echinomycin HIF-1alpha a…”
BackgroundShi, L., Pi, Y., Luo, C., Zhang, C., Tan, D., & Meng, X. (2015) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2015.06.004 · Cited by 22
Practical strategies for suppressing hypoxia-inducible factor activity in cancer therapy
McCarty, M. F., Barroso-Aranda, J., & Contreras, F. (2010) · Medical Hypotheses · doi:10.1016/j.mehy.2009.12.022 · Cited by 22
“they were able to identify twenty drugs which reduced this activity by >88% at a concentration of 400 nM [105].”
BackgroundPan, F., Barbi, J. J., & Pardoll, D. M. (2012) · OncoImmunology · doi:10.4161/onci.19457 · Cited by 22
“This cardiac glycoside was identified by the Semenza group to be a potent inhibitor of HIF-1 function.(15) Recently, the Littman group found that this compound and its derivatives were also potent antagonists of TH17 responses.”
The Roles of Hypoxia-Inducible Factors and Non-Coding RNAs in Gastrointestinal Cancer
Cho, H., Han, T., Hur, K., & Ban, H. S. (2019) · Genes · doi:10.3390/genes10121008 · Cited by 20
“Furthermore, overexpressing miR-22 in HCT116 cell lines reduces VEGF expression and represses cell growth and invasion by downregulating HIF-1α expression [50].”
BackgroundInfluentialIs digoxin use for cardiovascular disease associated with risk of prostate cancer?
Wright, J. L., Hansten, P. D., & Stanford, J. L. (2013) · The Prostate · doi:10.1002/pros.22733 · Cited by 20
“Recently, cardiac glycosides were shown to inhibit hypoxia inducible factor 1a (HIF-1a) protein expression both in vivo and in a mouse model [8,11].”
BackgroundPro-death and pro-survival properties of ouabain in U937 lymphoma derived cells
Cuozzo, F., Raciti, M., Bertelli, L., Parente, R., & Renzo, L. D. (2012) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-31-95 · Cited by 19
“In various cancer cell lines, including prostate cancer cells or breast tumor cells, cardiac glycosides induce apoptosis [11-16].”
BackgroundDigoxin use and the risk for colorectal cancer
Boursi, B., Haynes, K., Mamtani, R., & Yang, Y. (2014) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3717 · Cited by 21
Diacetoxyscirpenol as a new anticancer agent to target hypoxia-inducible factor 1
Choi, Y.-J., Shin, H., Chun, Y., Leutou, A. S., Son, B. W., & Park, J. (2016) · Oncotarget · doi:10.18632/oncotarget.11529 · Cited by 20
Makker, K., Afolayan, A. J., Teng, R., & Konduri, G. G. (2019) · Physiological Reports · doi:10.14814/phy2.13986 · Cited by 17
“Pharmacologic inhibition of HIF-1a using digoxin or inhibition of glycolysis with agents such as dichloro-acetate may offer insights into the role of these metabolic alterations in the impaired postnatal adaptation in PPHN (Koulmann et al. 2006; Zhang et al. 2008; Yoshida et al. 2010).”
Method
Metadata
- Authors
- Zhang, H., Qian, D. Z., Tan, Y. S., Lee, K., Gao, P., Ren, Y. R., Rey, S., Hammers, H., Chang, D., Pili, R., Dang, C. V., Liu, J. O., & Semenza, G. L.
- Affiliations
- Johns Hopkins University (US)
- Department of Oncology,
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2008-12-16
- Volume
- 105
- Issue
- 50
- Pages
- 19579-19586
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2604945
- OpenAlex
- W2135664375
- Semantic Scholar
- ad3fa6ccad907da0a52a0b821d2be70006a9b6fd
- Cited by
- 624
- References
- 40
- Citations by year
- 2026: 16 · 2025: 27 · 2024: 23 · 2023: 24 · 2022: 35 · 2021: 39 · 2020: 38 · 2019: 34 · 2018: 34 · 2017: 50 · 2016: 42 · 2015: 37 · 2014: 52 · 2013: 57 · 2012: 38
- FWCI
- 8.99
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Flight Attendant Medical Research Institute
- Johns Hopkins University
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- digoxin, cardiac glycosides, HIF-1α, HIF-1, tumor growth inhibition, drug screening, ouabain, proscillaridin A, tumor xenografts, cancer therapy
- MeSH terms
- Endothelial PAS Domain-Containing Protein 1, Animals, Antineoplastic Agents, Cardiac Glycosides, Digoxin, Humans, Transcription, Genetic, Transfection, Protein Biosynthesis, Mice, SCID, Genes, Reporter, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cell Proliferation, Luciferases, Firefly, Mice, Basic Helix-Loop-Helix Proteins, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.